NGNE
Price
$29.03
Change
-$4.96 (-14.59%)
Updated
Oct 17 closing price
Capitalization
414.31M
VRDN
Price
$24.21
Change
+$1.20 (+5.22%)
Updated
Oct 17 closing price
Capitalization
1.98B
30 days until earnings call
Interact to see
Advertisement

NGNE vs VRDN

Header iconNGNE vs VRDN Comparison
Open Charts NGNE vs VRDNBanner chart's image
Neurogene
Price$29.03
Change-$4.96 (-14.59%)
Volume$219.24K
Capitalization414.31M
Viridian Therapeutics
Price$24.21
Change+$1.20 (+5.22%)
Volume$1.27M
Capitalization1.98B
NGNE vs VRDN Comparison Chart in %
NGNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NGNE vs. VRDN commentary
Oct 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NGNE is a Hold and VRDN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 19, 2025
Stock price -- (NGNE: $29.03 vs. VRDN: $24.21)
Brand notoriety: NGNE and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NGNE: 119% vs. VRDN: 152%
Market capitalization -- NGNE: $414.31M vs. VRDN: $1.98B
NGNE [@Biotechnology] is valued at $414.31M. VRDN’s [@Biotechnology] market capitalization is $1.98B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NGNE’s FA Score shows that 0 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • NGNE’s FA Score: 0 green, 5 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, NGNE is a better buy in the long-term than VRDN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NGNE’s TA Score shows that 5 TA indicator(s) are bullish while VRDN’s TA Score has 4 bullish TA indicator(s).

  • NGNE’s TA Score: 5 bullish, 5 bearish.
  • VRDN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both NGNE and VRDN are a good buy in the short-term.

Price Growth

NGNE (@Biotechnology) experienced а -3.91% price change this week, while VRDN (@Biotechnology) price change was +15.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +15.88%, and the average quarterly price growth was +79.09%.

Reported Earning Dates

VRDN is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRDN($1.98B) has a higher market cap than NGNE($414M). NGNE (26.990) and VRDN (26.291) have similar YTD gains . NGNE has higher annual earnings (EBITDA): -81.25M vs. VRDN (-340.62M). VRDN has more cash in the bank: 563M vs. NGNE (275M). NGNE has less debt than VRDN: NGNE (12.9M) vs VRDN (21.3M). VRDN has higher revenues than NGNE: VRDN (305K) vs NGNE (0).
NGNEVRDNNGNE / VRDN
Capitalization414M1.98B21%
EBITDA-81.25M-340.62M24%
Gain YTD26.99026.291103%
P/E RatioN/AN/A-
Revenue0305K-
Total Cash275M563M49%
Total Debt12.9M21.3M61%
FUNDAMENTALS RATINGS
NGNE vs VRDN: Fundamental Ratings
NGNE
VRDN
OUTLOOK RATING
1..100
4332
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
92
Overvalued
PROFIT vs RISK RATING
1..100
10068
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
3738
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
8585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NGNE's Valuation (58) in the null industry is somewhat better than the same rating for VRDN (92) in the Biotechnology industry. This means that NGNE’s stock grew somewhat faster than VRDN’s over the last 12 months.

VRDN's Profit vs Risk Rating (68) in the Biotechnology industry is in the same range as NGNE (100) in the null industry. This means that VRDN’s stock grew similarly to NGNE’s over the last 12 months.

NGNE's SMR Rating (97) in the null industry is in the same range as VRDN (99) in the Biotechnology industry. This means that NGNE’s stock grew similarly to VRDN’s over the last 12 months.

NGNE's Price Growth Rating (37) in the null industry is in the same range as VRDN (38) in the Biotechnology industry. This means that NGNE’s stock grew similarly to VRDN’s over the last 12 months.

NGNE's P/E Growth Rating (100) in the null industry is in the same range as VRDN (100) in the Biotechnology industry. This means that NGNE’s stock grew similarly to VRDN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NGNEVRDN
RSI
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
Momentum
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
75%
MACD
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 5 days ago
84%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 18 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
NGNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HQIVX22.120.14
+0.64%
Hartford Equity Income R6
RYHRX41.740.24
+0.58%
Rydex Real Estate H
TEEFX86.830.29
+0.34%
T. Rowe Price Tax-Efficient Equity I
SUIAX62.92-0.15
-0.24%
DWS CROCI International A
ASQCX15.00-0.04
-0.27%
American Century Small Company C

NGNE and

Correlation & Price change

A.I.dvisor indicates that over the last year, NGNE has been loosely correlated with BRNS. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if NGNE jumps, then BRNS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NGNE
1D Price
Change %
NGNE100%
-14.59%
BRNS - NGNE
51%
Loosely correlated
-1.33%
RNAZ - NGNE
48%
Loosely correlated
+2.08%
ZNTL - NGNE
48%
Loosely correlated
-4.49%
SYRE - NGNE
44%
Loosely correlated
+1.03%
VRDN - NGNE
42%
Loosely correlated
+5.22%
More

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with NUVL. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
+5.22%
NUVL - VRDN
57%
Loosely correlated
+2.32%
SYRE - VRDN
55%
Loosely correlated
+1.03%
AGIO - VRDN
53%
Loosely correlated
+1.95%
KRYS - VRDN
53%
Loosely correlated
+1.01%
XNCR - VRDN
52%
Loosely correlated
-1.20%
More